Last reviewed · How we verify
A Randomised Phase III Study for Evaluating the Role of the Addition of Ovarian Function Suppression to Tamoxifen in Young Women With Hormone-Sensitive Breast Cancer Who Remain in Premenopause or Regain Menstruation After Chemotherapy (ASTRRA)
The purpose of this study is to compare 5-year disease free survival rate (DFS rate) between the hormone receptor positive breast cancer patients who were added Goserelin to Tamoxifen for ovarian function suppression after neo-/adjuvant cytotoxic chemotherapy and the hormone receptor positive breast cancer patients who were treated with Tamoxifen.
Details
| Lead sponsor | Korean Breast Cancer Study Group |
|---|---|
| Phase | Phase 3 |
| Status | UNKNOWN |
| Enrolment | 1234 |
| Start date | 2009-05 |
| Completion | 2015-12 |
Conditions
- Breast Cancer
Interventions
- goserelin
- tamoxifen
Primary outcomes
- all cause recurrence — the first 5 years after surgery
Countries
South Korea